Catasys, Inc. (CATS) Given Average Rating of “Buy” by Analysts
Shares of Catasys, Inc. (NASDAQ:CATS) have earned a consensus broker rating score of 2.00 (Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating. Catasys’ rating score has declined by 33.3% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a 12 month consensus target price of $5.30 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given Catasys an industry rank of 131 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Catasys from a “sell” rating to a “hold” rating in a research note on Thursday, February 8th.
Shares of Catasys (NASDAQ CATS) traded down $0.02 during trading hours on Thursday, hitting $4.46. 51,860 shares of the stock were exchanged, compared to its average volume of 70,713. The firm has a market cap of $69.44, a price-to-earnings ratio of -2.55 and a beta of 0.13. Catasys has a 12 month low of $3.30 and a 12 month high of $14.00.
ILLEGAL ACTIVITY WARNING: This article was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2018/02/22/catasys-inc-cats-given-average-rating-of-buy-by-analysts.html.
Catasys Company Profile
Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The companys OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.